Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) closed at $0.53 in the last session, up 3.44% from day before closing price of $0.51. In other words, the price has increased by $3.44 from its previous closing price. On the day, 1.01 million shares were traded. BCLI stock price reached its highest trading level at $0.61 during the session, while it also had its lowest trading level at $0.4533.
Ratios:
We take a closer look at BCLI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.24 and its Current Ratio is at 0.24.
Maxim Group reiterated its Buy rating for the stock on December 19, 2016, while the target price for the stock was revised from $5 to $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 01 ’23 when Lindborg Stacy bought 11,500 shares for $1.77 per share. The transaction valued at 20,402 led to the insider holds 181,500 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCLI now has a Market Capitalization of 36357892 and an Enterprise Value of 36332868.
Stock Price History:
Over the past 52 weeks, BCLI has reached a high of $3.37, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is 16.39%, while the 200-Day Moving Average is calculated to be -22.67%.
Shares Statistics:
According to the various share statistics, BCLI traded on average about 1.01M shares per day over the past 3-months and 1416970 shares per day over the past 10 days. A total of 60.49M shares are outstanding, with a floating share count of 56.13M. Insiders hold about 17.86% of the company’s shares, while institutions hold 5.92% stake in the company. Shares short for BCLI as of 1711584000 were 1343163 with a Short Ratio of 1.32, compared to 1709164800 on 1067002. Therefore, it implies a Short% of Shares Outstanding of 1343163 and a Short% of Float of 2.0499999.
Earnings Estimates
The market rating for Brainstorm Cell Therapeutics, Inc. (BCLI) is a result of the insights provided by BALI analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.53, with high estimates of $27.37 and low estimates of $10.91.
